Skip to main content

RNA

Stock
Health Care
Biotechnology

Performance overview

RNA Price
Price Chart

Forward-looking statistics

Beta
0.77
Risk
65.64%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Avidity Biosciences Inc is a biotechnology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product, AOC 1001, is designed to treat a rare monogenic muscle disease.

Company info

SectorHealth Care
IndustryBiotechnology
Employees226
Market cap$2.5B

Fundamentals

Enterprise value$2.0B
Revenue$8.9M
Revenue per employee—
Profit margin0.00%
Debt to equity0.45

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$3.00
Dividend per share—
Revenue per share$0.07
Avg trading volume (30 day)$43M
Avg trading volume (10 day)$29M
Put-call ratio—

Macro factor sensitivity

Growth+1.8
Credit+6.3
Liquidity-1.3
Inflation-1.0
Commodities-1.1
Interest Rates-0.4

Valuation

Dividend yield0.00%
PEG Ratio-9.38
Price to sales383.56
P/E Ratio-9.38
Enterprise Value to Revenue229.57
Price to book2.58

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients

Moderna stock jumps 4.5% as the FDA grants full approval for its COVID-19 vaccine in high-risk individuals aged six months to 11 years.

Zacks Investment Research (July 11, 2025)
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.'s MRNA supplemental Biologics License Application (sBLA) for Spikevax, the company's COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Benzinga (July 10, 2025)
Merck to Buy Verona Pharma for Around $10 Billion

Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.

Bloomberg Markets and Finance (July 9, 2025)
Verona Pharma Stock Jumps 20% on $10B Buyout Offer From Merck

VRNA jumps 20% after Merck unveils buyout to add COPD drug Ohtuvayre and reduce its reliance on Keytruda.

Zacks Investment Research (July 9, 2025)
New Strong Buy Stocks for July 7th

PRM, VRNA, SVNDY, TD and MSBHF have been added to the Zacks Rank #1 (Strong Buy) List on July 7, 2025.

Zacks Investment Research (July 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free